Kentucky biologics regulations.

Who may administer PRP, exosomes and stem cells in Kentucky, and which agencies to check.

A physician at a desk reading regulatory documents

Who may administer biologics in Kentucky?

In Kentucky, licensed medical professionals such as MDs and DOs with appropriate qualifications are eligible to administer biologics. Providers must also comply with state-specific licensing requirements, including Kentucky Board of Medical Licensure regulations for physicians.

Official sources

Kentucky compliance guide.

FDA Compliance

The U.S. Food and Drug Administration (FDA) regulates human cells, tissues, and cellular and tissue-based products (HCT/Ps). Kentucky providers offering biologics must comply with these federal standards to ensure that therapies are administered safely and ethically.

FDA’s 21 CFR Part 1271

FDA’s 21 CFR Part 1271 outlines requirements for HCT/P products, covering criteria such as donor eligibility, manufacturing practices, and labeling. Providers are advised to review these standards and confirm that treatments offered are either exempt or fall within the FDA’s guidelines for approved biologics.

Kentucky State Regulations

Kentucky has specific requirements regarding biologics administration. Clinics and practitioners must comply with the Kentucky Cabinet for Health and Family Services. For state-specific regulations, visit the Kentucky Department for Public Health website.

Provider Qualifications

In Kentucky, licensed medical professionals such as MDs and DOs with appropriate qualifications are eligible to administer biologics. Providers must also comply with state-specific licensing requirements, including Kentucky Board of Medical Licensure regulations for physicians.

Patient Informed Consent

To ensure transparency, providers should present a clear informed consent form that addresses:

  • The experimental nature of some stem cell therapies
  • Potential benefits and risks associated with treatment
  • Alternative treatment options
  • A statement that FDA approval may not cover all biologic therapies

Additional Compliance Considerations

Pre-Treatment and Post-Treatment Protocols

Implement detailed protocols to standardize patient assessments and post-treatment monitoring. These protocols improve patient safety and ensure compliance with regulatory expectations.

Standard Operating Procedures (SOPs)

Develop SOPs covering patient eligibility, treatment administration, and infection control to meet state and federal safety standards.

Medical Liability Insurance

Secure a comprehensive insurance policy that covers biologic treatments, ensuring adequate liability protection for the clinic and staff.

Marketing Compliance

Advertise responsibly by avoiding unverified claims and adhering to both FDA and FTC guidelines. Include disclaimers when promoting stem cell therapies, emphasizing any limitations in research support or FDA approval.

This guide is a general summary to help clinics understand compliance requirements for biologics in Kentucky. It is not legal advice. Regulations change; consult legal counsel and the agencies above before acting on it.

Kentucky: common questions.

Who can administer stem cells, PRP and exosomes in Kentucky?
In Kentucky, licensed medical professionals such as MDs and DOs with appropriate qualifications are eligible to administer biologics. Providers must also comply with state-specific licensing requirements, including Kentucky Board of Medical Licensure regulations for physicians. This is a general summary, not legal advice. Confirm with the state board.
Are stem cell and exosome therapies FDA-approved in Kentucky?
FDA rules are federal, so they apply in Kentucky as everywhere else. Exosome and stem cell therapies are not FDA-approved for therapeutic use, and PRP applications are considered off-label.
Do I need an IRB-approved study to offer biologics in Kentucky?
Investigational treatment belongs inside a reviewed study with proper informed consent. IRB review is not FDA authorisation: culture-expanded and other more-than-minimally-manipulated cell products generally need an IND before use in people.
How do I start offering biologics in Kentucky?
Start with the live webinar, then a discovery call and live training. After that we verify your Kentucky licence, protocol, product sourcing, consent process and advertising before you are listed for patient inquiries.

Practising in Kentucky? Start with the webinar.

Live on Zoom, Tuesdays at 12:00 PM ET. See how the model works before you commit to anything.